安博诺和海捷亚治疗原发性高血压的疗效比较 - 第三军医大学学报.doc

安博诺和海捷亚治疗原发性高血压的疗效比较 邓国兰 陈泓颖 （重庆医科大学附属第一医院心内科，重庆 400016） [摘要] 目的： 本研究旨在对比评价安博诺（每片含厄贝沙坦150mg/氢氯塞嗪12.5mg）和海捷亚（每片含氯沙坦钾50mg/氢氯塞嗪12.5mg）治疗原发性高血压的疗效、安全性和耐受性。方法：签署知情同意书的48例原发性高血压病人，停服各种降血压药物和血管活性药物，坐位三次平均血压符合SBP140~180 mmHg和DBP95~115mmHg。按患者入组的先后顺序随机分为2组各24例，治疗组安博诺每天一片治疗4周，对照组海捷亚每天一片治疗4周，服药时间统一为上午7：00~8：00时。观察2组治疗前后血压、心率、肝功、肾功、血糖、血脂、电解质及不良反应。结果：2组用药后2周、4周血压明显降低（P＜0.01，P＜0.05）；组间比较安博诺组2周、4周的总有效率分别高于海捷亚组治疗后（P＜0.05有显著性差异）；安博诺组治疗后2周 与4周 SBP、 DBP的降压幅度分别大于海捷亚组治疗后（P＜0.05有显著性差异）；2组治疗前后心率、生化指标变化无统计学意义（P＞0.05）；2组无明显不良发应，组间不良发应发生率无统计学意义（P＞0.05）。结论： 2组降压疗效明确，安博诺组降压幅度大于海捷亚组，安全性与耐受性同海捷亚。 [关键词] 安博诺；海捷亚；原发性高血压；疗效；安全性 【中国图书分类法分类号】 R544.1 【文献标识码】 A 【收稿日期】2008-07-23 Efficacy of COAPROVEL for primary hypertension compared with HYZAAR DEND Guo-Lan，et al （Department of Cardiology,the First Affiliated Hospital ， Chongqing Medical University) 【Abstract】 Objective: To compare the efficacy, security and tolerance of COAPROVEL (Irbesartan 150mg and Hydrochlorothiazide 12.5mg per tablet) and HYZAAR (150mg Losartan and 12.5mg Hydrochlorothiazide per tablet)for primary hypertension. Methods: A total of 48 primary hypertensive patients of signed informed consent were enrolled，and required to stop all antihypertensive and vasoactive drugs. Their average systolic blood pressure(SBP) was between 140 ~180mmHg and average diastolic blood pressure(DBP) between 95 ~ 115mmHg by three times’ detection of sitting posture. According to the order which patients were brought into groups patients were randomized, COAPROVEL group and HYZAAR group, each with 24 persons. Those in the treatment group were given one tablet of COAPROVEL for 4 wk at 7am to 8am in the morning, while others were given one tablet of HYZAAR as the control group. Blood pressure, heart rate, liver function, renal function, glucose, lipids and electrolyte were observed before and after treatment and adverse effect incidence rate of the medicine was also observed . Results: BP declined significantly in both groups at 2 wk and 4 wk of